800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Study to Evaluate XEN1101 As Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)

view all Clinical Trials

Overview

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Clinical Trial Information

Protocol

NCT05614063 IRB#: 31589

Phase

3

Condition(s)

Seizures

Investigator

Mercedes P. Jacobson, MD, Valeriya Poukas, MD and Avani A. Shah, MD

Coordinator

Kathleen Hatala, RN, BSN
215-707-4171

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-4171 or email [email protected].

Full Title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 As Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures